{"classes":[{"categories":[{"measurements":[{"comment":"30 patients were treated, 2 patients achieved objective response. The duration of response was 5 months and 18.7 months for the 2 patients who achieved objective response.","groupId":"OG000","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"}],"units":"Participants"}],"description":"The interval from which measurement criteria are first met for Complete Response (CR) or Partial Response (PR) until the first date that progressive disease is objectively documented","groups":[{"description":"During the treatment phase of the study, eligible patients will receive assigned treatments in 3 week cycles until progression.\n\nCDX-3379 and cetuximab: Dose: 12 mg/kg CDX-3379 once every 3 weeks in combination with 400 mg/m2 cetuximab on the first day followed by weekly doses of 250 mg/m2 cetuximab.","id":"OG000","title":"CDX-3379 and Cetuximab"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"First occurrence of a documented objective response to disease progression or death (up to approximately 2 years)","title":"Duration of Response (DOR)","type":"SECONDARY","unitOfMeasure":"months"}